UY25299A1 - Combinaciones de estatina-eter carboxialquílico - Google Patents
Combinaciones de estatina-eter carboxialquílicoInfo
- Publication number
- UY25299A1 UY25299A1 UY25299A UY25299A UY25299A1 UY 25299 A1 UY25299 A1 UY 25299A1 UY 25299 A UY25299 A UY 25299A UY 25299 A UY25299 A UY 25299A UY 25299 A1 UY25299 A1 UY 25299A1
- Authority
- UY
- Uruguay
- Prior art keywords
- statin
- carboxyalkyl ether
- cholesterol
- combination
- density lipoprotein
- Prior art date
Links
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 title abstract 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 4
- 102000015779 HDL Lipoproteins Human genes 0.000 abstract 2
- 108010010234 HDL Lipoproteins Proteins 0.000 abstract 2
- 102000007330 LDL Lipoproteins Human genes 0.000 abstract 2
- 108010007622 LDL Lipoproteins Proteins 0.000 abstract 2
- 235000012000 cholesterol Nutrition 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- SDMBRCRVFFHJKR-UHFFFAOYSA-N 6-(5-carboxy-5-methylhexoxy)-2,2-dimethylhexanoic acid Chemical compound OC(=O)C(C)(C)CCCCOCCCCC(C)(C)C(O)=O SDMBRCRVFFHJKR-UHFFFAOYSA-N 0.000 abstract 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 abstract 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 abstract 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 1
- 229960005370 atorvastatin Drugs 0.000 abstract 1
- 125000004181 carboxyalkyl group Chemical group 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000036470 plasma concentration Effects 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6937597P | 1997-12-12 | 1997-12-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY25299A1 true UY25299A1 (es) | 2001-08-27 |
Family
ID=22088573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY25299A UY25299A1 (es) | 1997-12-12 | 1998-12-11 | Combinaciones de estatina-eter carboxialquílico |
Country Status (30)
| Country | Link |
|---|---|
| EP (1) | EP1045691B1 (https=) |
| JP (1) | JP2002508320A (https=) |
| KR (1) | KR20010033003A (https=) |
| AR (1) | AR017851A1 (https=) |
| AT (1) | ATE285762T1 (https=) |
| AU (1) | AU754089B2 (https=) |
| BR (1) | BR9813542A (https=) |
| CA (1) | CA2304612A1 (https=) |
| CO (1) | CO4970816A1 (https=) |
| CR (1) | CR5926A (https=) |
| CU (1) | CU20000140A7 (https=) |
| DE (1) | DE69828442T2 (https=) |
| DK (1) | DK1045691T3 (https=) |
| ES (1) | ES2230733T3 (https=) |
| GT (1) | GT199800196A (https=) |
| HN (1) | HN1998000185A (https=) |
| HU (1) | HUP0004547A3 (https=) |
| IL (1) | IL135349A0 (https=) |
| IS (1) | IS2150B (https=) |
| MY (1) | MY118381A (https=) |
| NO (1) | NO20002966D0 (https=) |
| NZ (1) | NZ503982A (https=) |
| PA (1) | PA8464601A1 (https=) |
| PE (1) | PE20000017A1 (https=) |
| PL (1) | PL341066A1 (https=) |
| PT (1) | PT1045691E (https=) |
| SV (1) | SV1998000146A (https=) |
| UY (1) | UY25299A1 (https=) |
| WO (1) | WO1999030704A1 (https=) |
| ZA (1) | ZA9811348B (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6861555B2 (en) | 2000-01-25 | 2005-03-01 | Warner-Lambert Company | Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith |
| EP1037623A1 (en) * | 1997-12-12 | 2000-09-27 | Warner-Lambert Company | Antihyperlipidemic statin-lp(a) inhibitor combinations |
| US20030105154A1 (en) | 2001-10-24 | 2003-06-05 | Bisgaier Charles Larry | Statin-carboxyalkylether combinations |
| CZ20011035A3 (cs) * | 1998-09-30 | 2001-10-17 | Warner-Lambert Company | Léčivo pro prevenci nebo oddálení revaskularizace pomocí katetru u pacientů postiľených chorobou koronární artérie |
| US6562864B1 (en) * | 1999-09-02 | 2003-05-13 | Drake Larson | Catechin multimers as therapeutic drug delivery agents |
| IN191580B (https=) * | 1999-12-17 | 2003-12-06 | Ranbaxy Lab Ltd | |
| CA2397960C (en) | 2000-01-25 | 2008-09-09 | Warner-Lambert Company | Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith |
| AU2001256278A1 (en) * | 2000-04-18 | 2001-10-30 | Bayer Aktiengesellschaft | Use of cse inhibitors for treating heart failure |
| OA12252A (en) * | 2000-04-26 | 2006-05-11 | Warner Lambert Co | Antihypertensive agents and use. |
| US6689807B1 (en) | 2000-06-08 | 2004-02-10 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | HMG CoA reductase inhibitors for promoting angiogenesis |
| US6777552B2 (en) | 2001-08-16 | 2004-08-17 | Teva Pharmaceutical Industries, Ltd. | Processes for preparing calcium salt forms of statins |
| HRPK20040255B3 (en) * | 2001-08-16 | 2006-02-28 | Teva Pharmaceutical Industries Ltd. | Processes for preparing calcium salt forms of statins |
| US20050026979A1 (en) * | 2003-07-31 | 2005-02-03 | Maha Ghazzi | Methods for treating inflammation and inflammation-associated diseases with a statin and ether |
| US10028926B2 (en) * | 2012-01-06 | 2018-07-24 | Gemphire Therapeutics Inc. | Methods of reducing risk of cardiovascular disease |
| AU2016348638A1 (en) | 2015-11-06 | 2018-06-07 | Gemphire Therapeutics Inc. | Gemcabene combinations for the treatment of cardiovascular disease |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5648387A (en) * | 1995-03-24 | 1997-07-15 | Warner-Lambert Company | Carboxyalkylethers, formulations, and treatment of vascular diseases |
-
1998
- 1998-11-12 NZ NZ503982A patent/NZ503982A/en unknown
- 1998-11-20 DE DE69828442T patent/DE69828442T2/de not_active Expired - Lifetime
- 1998-11-20 PL PL98341066A patent/PL341066A1/xx unknown
- 1998-11-20 CA CA002304612A patent/CA2304612A1/en not_active Abandoned
- 1998-11-20 KR KR1020007006355A patent/KR20010033003A/ko not_active Ceased
- 1998-11-20 PT PT98960278T patent/PT1045691E/pt unknown
- 1998-11-20 IL IL13534998A patent/IL135349A0/xx unknown
- 1998-11-20 BR BR9813542-2A patent/BR9813542A/pt not_active Application Discontinuation
- 1998-11-20 JP JP2000538687A patent/JP2002508320A/ja active Pending
- 1998-11-20 HU HU0004547A patent/HUP0004547A3/hu unknown
- 1998-11-20 AT AT98960278T patent/ATE285762T1/de not_active IP Right Cessation
- 1998-11-20 AU AU15915/99A patent/AU754089B2/en not_active Ceased
- 1998-11-20 DK DK98960278T patent/DK1045691T3/da active
- 1998-11-20 ES ES98960278T patent/ES2230733T3/es not_active Expired - Lifetime
- 1998-11-20 WO PCT/US1998/024679 patent/WO1999030704A1/en not_active Ceased
- 1998-11-20 EP EP98960278A patent/EP1045691B1/en not_active Expired - Lifetime
- 1998-12-09 HN HN1998000185A patent/HN1998000185A/es unknown
- 1998-12-10 MY MYPI98005579A patent/MY118381A/en unknown
- 1998-12-10 ZA ZA9811348A patent/ZA9811348B/xx unknown
- 1998-12-10 CR CR5926A patent/CR5926A/es not_active Application Discontinuation
- 1998-12-11 CO CO98073828A patent/CO4970816A1/es unknown
- 1998-12-11 PE PE1998001207A patent/PE20000017A1/es not_active Application Discontinuation
- 1998-12-11 GT GT199800196A patent/GT199800196A/es unknown
- 1998-12-11 UY UY25299A patent/UY25299A1/es not_active Application Discontinuation
- 1998-12-11 PA PA19988464601A patent/PA8464601A1/es unknown
- 1998-12-11 AR ARP980106321A patent/AR017851A1/es unknown
- 1998-12-11 SV SV1998000146A patent/SV1998000146A/es not_active Application Discontinuation
-
2000
- 2000-04-14 IS IS5445A patent/IS2150B/is unknown
- 2000-06-09 CU CU20000140A patent/CU20000140A7/es unknown
- 2000-06-09 NO NO20002966A patent/NO20002966D0/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY25299A1 (es) | Combinaciones de estatina-eter carboxialquílico | |
| DK0738512T3 (da) | Fremgangsmåde til forebyggelse af et andet hjerteanfald ved anvendelse af en HMG coenzsym A reduktasehæmmer | |
| AR004527A1 (es) | Composicion farmaceutica para regular la concentracion de lipidos en un mamifero | |
| GT199800166A (es) | Combinacion de un inhibidor de la aldosa reductasa y un inhibidor de la glucogeno fosforilasa. | |
| ES2188285T3 (es) | Combinaciones de inhibidores del transporte de acidos biliares ileales y derivados de acido nicotinico para indicaciones cardiovasculares. | |
| AR015487A1 (es) | Uso de un compuesto de colesterol hidroxilado como agente reductor para preparar una composicion farmaceutica de utilidad en un metodo para inhibirla oxidacion de las lipoproteinas en un mamifero. | |
| BR9808013A (pt) | Terapia de combinação empregando benzotiepinas de inibição de transporte de ácido biliar ileal e inibidores de redutase de hmg co-a | |
| BR9809793A (pt) | Monoésteres de probucol para o tratamento de doença inflamatória e cardiovascular | |
| ES2176755T3 (es) | Derivados anticonvulsivos utiles para el tratamiento de la esclerosis lateral amiotrofica. | |
| BR9712285A (pt) | Tetrafosfonato bicìclico de trianidridas | |
| AU6503099A (en) | Automatic generation of acpi source language for peripheral resource configuration | |
| CA2390295A1 (en) | A method for chemoprevention of prostate cancer | |
| BR0112365A (pt) | Combinações de estatinas, agentes estrogênicos e opcionalmente estrogênios | |
| EP0276807A3 (en) | Lipid regulating compositions | |
| ES2177642T3 (es) | Uso de ciertos derivados de acido metanobisfosfonico para prevenir el desprendimiento y la migracion de protesis. | |
| CL2004000026A1 (es) | Uso de una composicion que comprende 0 a alrededor de 29% de cis-clomifeno y de alrededor de 100 a alrededor de 71% de trans-clomifeno para preparar un medicamento util para aumentar los niveles de testosterona en suero en un mamifero masculino. | |
| WO1998057620A3 (en) | Inositol for modulation of immune response | |
| EP1132426A3 (en) | Laminated film comprising a polyolefin resin composition | |
| AU2558300A (en) | Substituted stilbene compounds with vascular damaging activity | |
| BR9712353A (pt) | Agentes de limpeza | |
| ES2161750T3 (es) | Uso de 17alfa-dihidroequilenina para disminuir el nivel de colesterol. | |
| UY25436A1 (es) | Combinaciones de estatina-inhibidor de mmp | |
| WO2003045311A3 (en) | Methods for inhibiting or suppressing stenosis of arteriovenous access fistulas and grafts | |
| HK1039277A1 (zh) | 改善庫存及/或用過的各種光敏治療系統及其成分的穩定性的方法 | |
| ECSP982777A (es) | Combinaciones de estatina- - eter carboxialquilico. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20121217 |